The Experts below are selected from a list of 150687 Experts worldwide ranked by ideXlab platform
David M Omalley - One of the best experts on this subject based on the ideXlab platform.
-
mirvetuximab soravtansine a folate receptor alpha frα targeting Antibody drug conjugate adc in combination with bevacizumab in patients pts with platinum resistant ovarian cancer final findings from the forward ii study
Journal of Clinical Oncology, 2019Co-Authors: David M Omalley, Ursula A Matulonis, Lucy Gilbert, Ignace Vergote, Cesar M Castro, Antonio Gonzalezmartin, Gina Mantiasmaldone, Raquel BratosAbstract:5520Background: Mirvetuximab soravtansine is an ADC comprising a FRα-Binding Antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent. As part of the Phase 1b FORWARD ...
-
mirvetuximab soravtansine a folate receptor alpha frα targeting Antibody drug conjugate adc in combination with bevacizumab in patients pts with platinum resistant ovarian cancer maturing safety and activity profile from the forward ii phase 1b study
Journal of Clinical Oncology, 2018Co-Authors: David M Omalley, Ursula A Matulonis, Lucy Gilbert, Ignace Vergote, Cesar M Castro, Karim Malek, Antonio Gonzalezmartin, Kathleen N MooreAbstract:5549Background: Mirvetuximab soravtansine is an ADC, comprising a FRα-Binding Antibody linked to the tubulin-disrupting maytansinoid DM4, currently being evaluated in combination with bevacizumab a...
-
mirvetuximab soravtansine imgn853 a folate receptor alpha frα targeting Antibody drug conjugate adc in platinum resistant epithelial ovarian cancer eoc patients pts activity and safety analyses in phase i pooled expansion cohorts
Journal of Clinical Oncology, 2017Co-Authors: Kathleen N Moore, David M Omalley, Ursula A Matulonis, Jason A Konner, Raymond P Perez, Todd Michael Bauer, Lucy Gilbert, Shelly Seward, Rodrigo RuizsotoAbstract:5547Background: The early clinical evaluation of mirvetuximab soravtansine (IMGN853), an ADC that comprises a FRα-Binding Antibody linked to the tubulin-disrupting maytansinoid DM4, has revealed en...
-
imgn853 mirvetuximab soravtansine a folate receptor alpha frα targeting Antibody drug conjugate adc single agent activity in platinum resistant epithelial ovarian cancer eoc patients pts
Journal of Clinical Oncology, 2016Co-Authors: Kathleen N Moore, David M Omalley, Ursula A Matulonis, Jason A Konner, Raymond P Perez, Todd Michael Bauer, Shelly Seward, Woondong Jeong, Lainie P Martin, Yinghui ZhouAbstract:5567Background: IMGN853 (mirvetuximab soravtansine) is an ADC, comprising a FRα-Binding Antibody linked to the tubulin-disrupting maytansinoid, DM4. Here we report on the IMGN853 monotherapy expans...
-
preliminary single agent activity of imgn853 a folate receptor alpha fr alpha targeting Antibody drug conjugate adc in platinum resistant epithelial ovarian cancer eoc patients pts phase i trial
Journal of Clinical Oncology, 2015Co-Authors: Kathleen N Moore, David M Omalley, Raymond P Perez, Todd Michael Bauer, Shelly Seward, Woondong Jeong, Maurice Kirby, Yinghui Zhou, Mary F MichenzieAbstract:5518 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC that comprises a FRα-Binding Antibody conjugated with the potent maytansinoid, DM4. Methods: This phase I trial evaluates the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of IMGN853 in pts with FRα-positive solid tumors. A recommended phase II dose (RP2D) of 6.0 mg/kg, administered once every three weeks using adjusted ideal body weight was established in the dose-finding phase. Preliminary evidence of antitumor activity is being investigated at the RP2D in disease-specific cohorts of pts with platinum-resistant EOC and relapsed/refractory endometrial carcinoma. Here we report preliminary clinical activity (partial PR or complete CR response, CA125 response, SD ≥ 6 cycles) at the RP2D in pts with platinum-resistant EOC. Results: To date, 14 platinum-resistant EOC pts have been treated at the RP2D: 2 in dose escalation; 12 in the expansion cohort. All pts were heavily pretreated (mean: 4.5; range 2-12 prior tr...
Kathleen N Moore - One of the best experts on this subject based on the ideXlab platform.
-
mirvetuximab soravtansine a folate receptor alpha frα targeting Antibody drug conjugate adc in combination with bevacizumab in patients pts with platinum resistant ovarian cancer maturing safety and activity profile from the forward ii phase 1b study
Journal of Clinical Oncology, 2018Co-Authors: David M Omalley, Ursula A Matulonis, Lucy Gilbert, Ignace Vergote, Cesar M Castro, Karim Malek, Antonio Gonzalezmartin, Kathleen N MooreAbstract:5549Background: Mirvetuximab soravtansine is an ADC, comprising a FRα-Binding Antibody linked to the tubulin-disrupting maytansinoid DM4, currently being evaluated in combination with bevacizumab a...
-
mirvetuximab soravtansine imgn853 a folate receptor alpha frα targeting Antibody drug conjugate adc in platinum resistant epithelial ovarian cancer eoc patients pts activity and safety analyses in phase i pooled expansion cohorts
Journal of Clinical Oncology, 2017Co-Authors: Kathleen N Moore, David M Omalley, Ursula A Matulonis, Jason A Konner, Raymond P Perez, Todd Michael Bauer, Lucy Gilbert, Shelly Seward, Rodrigo RuizsotoAbstract:5547Background: The early clinical evaluation of mirvetuximab soravtansine (IMGN853), an ADC that comprises a FRα-Binding Antibody linked to the tubulin-disrupting maytansinoid DM4, has revealed en...
-
imgn853 mirvetuximab soravtansine a folate receptor alpha frα targeting Antibody drug conjugate adc single agent activity in platinum resistant epithelial ovarian cancer eoc patients pts
Journal of Clinical Oncology, 2016Co-Authors: Kathleen N Moore, David M Omalley, Ursula A Matulonis, Jason A Konner, Raymond P Perez, Todd Michael Bauer, Shelly Seward, Woondong Jeong, Lainie P Martin, Yinghui ZhouAbstract:5567Background: IMGN853 (mirvetuximab soravtansine) is an ADC, comprising a FRα-Binding Antibody linked to the tubulin-disrupting maytansinoid, DM4. Here we report on the IMGN853 monotherapy expans...
-
preliminary single agent activity of imgn853 a folate receptor alpha fr alpha targeting Antibody drug conjugate adc in platinum resistant epithelial ovarian cancer eoc patients pts phase i trial
Journal of Clinical Oncology, 2015Co-Authors: Kathleen N Moore, David M Omalley, Raymond P Perez, Todd Michael Bauer, Shelly Seward, Woondong Jeong, Maurice Kirby, Yinghui Zhou, Mary F MichenzieAbstract:5518 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC that comprises a FRα-Binding Antibody conjugated with the potent maytansinoid, DM4. Methods: This phase I trial evaluates the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of IMGN853 in pts with FRα-positive solid tumors. A recommended phase II dose (RP2D) of 6.0 mg/kg, administered once every three weeks using adjusted ideal body weight was established in the dose-finding phase. Preliminary evidence of antitumor activity is being investigated at the RP2D in disease-specific cohorts of pts with platinum-resistant EOC and relapsed/refractory endometrial carcinoma. Here we report preliminary clinical activity (partial PR or complete CR response, CA125 response, SD ≥ 6 cycles) at the RP2D in pts with platinum-resistant EOC. Results: To date, 14 platinum-resistant EOC pts have been treated at the RP2D: 2 in dose escalation; 12 in the expansion cohort. All pts were heavily pretreated (mean: 4.5; range 2-12 prior tr...
-
preliminary single agent activity of imgn853 a folate receptor alpha fr alpha targeting Antibody drug conjugate adc in platinum resistant epithelial ovarian cancer eoc patients pts phase i trial
Journal of Clinical Oncology, 2015Co-Authors: Kathleen N Moore, David M Omalley, Raymond P Perez, Todd Michael Bauer, Shelly Seward, Woondong Jeong, Maurice Kirby, Lainie P Martin, Amit M Oza, Yinghui ZhouAbstract:5518 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC that comprises a FRα-Binding Antibody conjugated with the potent maytansinoid, DM4. Methods: This phase I trial evaluates...
Todd Michael Bauer - One of the best experts on this subject based on the ideXlab platform.
-
mirvetuximab soravtansine imgn853 a folate receptor alpha frα targeting Antibody drug conjugate adc in platinum resistant epithelial ovarian cancer eoc patients pts activity and safety analyses in phase i pooled expansion cohorts
Journal of Clinical Oncology, 2017Co-Authors: Kathleen N Moore, David M Omalley, Ursula A Matulonis, Jason A Konner, Raymond P Perez, Todd Michael Bauer, Lucy Gilbert, Shelly Seward, Rodrigo RuizsotoAbstract:5547Background: The early clinical evaluation of mirvetuximab soravtansine (IMGN853), an ADC that comprises a FRα-Binding Antibody linked to the tubulin-disrupting maytansinoid DM4, has revealed en...
-
imgn853 mirvetuximab soravtansine a folate receptor alpha frα targeting Antibody drug conjugate adc single agent activity in platinum resistant epithelial ovarian cancer eoc patients pts
Journal of Clinical Oncology, 2016Co-Authors: Kathleen N Moore, David M Omalley, Ursula A Matulonis, Jason A Konner, Raymond P Perez, Todd Michael Bauer, Shelly Seward, Woondong Jeong, Lainie P Martin, Yinghui ZhouAbstract:5567Background: IMGN853 (mirvetuximab soravtansine) is an ADC, comprising a FRα-Binding Antibody linked to the tubulin-disrupting maytansinoid, DM4. Here we report on the IMGN853 monotherapy expans...
-
preliminary single agent activity of imgn853 a folate receptor alpha fr alpha targeting Antibody drug conjugate adc in platinum resistant epithelial ovarian cancer eoc patients pts phase i trial
Journal of Clinical Oncology, 2015Co-Authors: Kathleen N Moore, David M Omalley, Raymond P Perez, Todd Michael Bauer, Shelly Seward, Woondong Jeong, Maurice Kirby, Yinghui Zhou, Mary F MichenzieAbstract:5518 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC that comprises a FRα-Binding Antibody conjugated with the potent maytansinoid, DM4. Methods: This phase I trial evaluates the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of IMGN853 in pts with FRα-positive solid tumors. A recommended phase II dose (RP2D) of 6.0 mg/kg, administered once every three weeks using adjusted ideal body weight was established in the dose-finding phase. Preliminary evidence of antitumor activity is being investigated at the RP2D in disease-specific cohorts of pts with platinum-resistant EOC and relapsed/refractory endometrial carcinoma. Here we report preliminary clinical activity (partial PR or complete CR response, CA125 response, SD ≥ 6 cycles) at the RP2D in pts with platinum-resistant EOC. Results: To date, 14 platinum-resistant EOC pts have been treated at the RP2D: 2 in dose escalation; 12 in the expansion cohort. All pts were heavily pretreated (mean: 4.5; range 2-12 prior tr...
-
phase 1 study of imgn853 a folate receptor alpha fr alpha targeting Antibody drug conjugate adc in patients pts with epithelial ovarian cancer eoc and other fra positive solid tumors
Journal of Clinical Oncology, 2015Co-Authors: Hossein Borghaei, David M Omalley, Raymond P Perez, Todd Michael Bauer, Shelly Seward, Woondong Jeong, Maurice Kirby, Mary F Michenzie, Gurudatt Chandorkar, Rodrigo RuizsotoAbstract:5558 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC comprising a FRα-Binding Antibody and potent maytansinoid, DM4. Methods: This Phase 1 trial is being conducted to determine safety, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, recommended phase 2 dose (RP2D) and evidence of activity of IMGN853 in pts with EOC or other FRa-positive solid tumors. As previously reported, the occurrence of ocular adverse events (AEs) was associated with peak drug exposure and pt weight. Dosing by adjusted ideal body weight (AIBW) instead of total body weight (TBW) was implemented to decrease PK variability. Two dosing schedules are being evaluated; (A) once every 3 weeks and (B) Days 1, 8, and 15, every 4 weeks. Results: Fifty nine pts enrolled to dose escalation to date, 44 (30 TBW; 14 AIBW) pts in A, 16 (AIBW) in B. RP2D for A was determined to be 6.0 mg/kg, while dose finding in B continues. Exposure to IMGN853 increased with an increase in dose in a more than dose-proportional...
-
preliminary single agent activity of imgn853 a folate receptor alpha fr alpha targeting Antibody drug conjugate adc in platinum resistant epithelial ovarian cancer eoc patients pts phase i trial
Journal of Clinical Oncology, 2015Co-Authors: Kathleen N Moore, David M Omalley, Raymond P Perez, Todd Michael Bauer, Shelly Seward, Woondong Jeong, Maurice Kirby, Lainie P Martin, Amit M Oza, Yinghui ZhouAbstract:5518 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC that comprises a FRα-Binding Antibody conjugated with the potent maytansinoid, DM4. Methods: This phase I trial evaluates...
Raymond P Perez - One of the best experts on this subject based on the ideXlab platform.
-
mirvetuximab soravtansine imgn853 a folate receptor alpha frα targeting Antibody drug conjugate adc in platinum resistant epithelial ovarian cancer eoc patients pts activity and safety analyses in phase i pooled expansion cohorts
Journal of Clinical Oncology, 2017Co-Authors: Kathleen N Moore, David M Omalley, Ursula A Matulonis, Jason A Konner, Raymond P Perez, Todd Michael Bauer, Lucy Gilbert, Shelly Seward, Rodrigo RuizsotoAbstract:5547Background: The early clinical evaluation of mirvetuximab soravtansine (IMGN853), an ADC that comprises a FRα-Binding Antibody linked to the tubulin-disrupting maytansinoid DM4, has revealed en...
-
imgn853 mirvetuximab soravtansine a folate receptor alpha frα targeting Antibody drug conjugate adc single agent activity in platinum resistant epithelial ovarian cancer eoc patients pts
Journal of Clinical Oncology, 2016Co-Authors: Kathleen N Moore, David M Omalley, Ursula A Matulonis, Jason A Konner, Raymond P Perez, Todd Michael Bauer, Shelly Seward, Woondong Jeong, Lainie P Martin, Yinghui ZhouAbstract:5567Background: IMGN853 (mirvetuximab soravtansine) is an ADC, comprising a FRα-Binding Antibody linked to the tubulin-disrupting maytansinoid, DM4. Here we report on the IMGN853 monotherapy expans...
-
preliminary single agent activity of imgn853 a folate receptor alpha fr alpha targeting Antibody drug conjugate adc in platinum resistant epithelial ovarian cancer eoc patients pts phase i trial
Journal of Clinical Oncology, 2015Co-Authors: Kathleen N Moore, David M Omalley, Raymond P Perez, Todd Michael Bauer, Shelly Seward, Woondong Jeong, Maurice Kirby, Yinghui Zhou, Mary F MichenzieAbstract:5518 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC that comprises a FRα-Binding Antibody conjugated with the potent maytansinoid, DM4. Methods: This phase I trial evaluates the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of IMGN853 in pts with FRα-positive solid tumors. A recommended phase II dose (RP2D) of 6.0 mg/kg, administered once every three weeks using adjusted ideal body weight was established in the dose-finding phase. Preliminary evidence of antitumor activity is being investigated at the RP2D in disease-specific cohorts of pts with platinum-resistant EOC and relapsed/refractory endometrial carcinoma. Here we report preliminary clinical activity (partial PR or complete CR response, CA125 response, SD ≥ 6 cycles) at the RP2D in pts with platinum-resistant EOC. Results: To date, 14 platinum-resistant EOC pts have been treated at the RP2D: 2 in dose escalation; 12 in the expansion cohort. All pts were heavily pretreated (mean: 4.5; range 2-12 prior tr...
-
phase 1 study of imgn853 a folate receptor alpha fr alpha targeting Antibody drug conjugate adc in patients pts with epithelial ovarian cancer eoc and other fra positive solid tumors
Journal of Clinical Oncology, 2015Co-Authors: Hossein Borghaei, David M Omalley, Raymond P Perez, Todd Michael Bauer, Shelly Seward, Woondong Jeong, Maurice Kirby, Mary F Michenzie, Gurudatt Chandorkar, Rodrigo RuizsotoAbstract:5558 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC comprising a FRα-Binding Antibody and potent maytansinoid, DM4. Methods: This Phase 1 trial is being conducted to determine safety, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, recommended phase 2 dose (RP2D) and evidence of activity of IMGN853 in pts with EOC or other FRa-positive solid tumors. As previously reported, the occurrence of ocular adverse events (AEs) was associated with peak drug exposure and pt weight. Dosing by adjusted ideal body weight (AIBW) instead of total body weight (TBW) was implemented to decrease PK variability. Two dosing schedules are being evaluated; (A) once every 3 weeks and (B) Days 1, 8, and 15, every 4 weeks. Results: Fifty nine pts enrolled to dose escalation to date, 44 (30 TBW; 14 AIBW) pts in A, 16 (AIBW) in B. RP2D for A was determined to be 6.0 mg/kg, while dose finding in B continues. Exposure to IMGN853 increased with an increase in dose in a more than dose-proportional...
-
preliminary single agent activity of imgn853 a folate receptor alpha fr alpha targeting Antibody drug conjugate adc in platinum resistant epithelial ovarian cancer eoc patients pts phase i trial
Journal of Clinical Oncology, 2015Co-Authors: Kathleen N Moore, David M Omalley, Raymond P Perez, Todd Michael Bauer, Shelly Seward, Woondong Jeong, Maurice Kirby, Lainie P Martin, Amit M Oza, Yinghui ZhouAbstract:5518 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC that comprises a FRα-Binding Antibody conjugated with the potent maytansinoid, DM4. Methods: This phase I trial evaluates...
Shelly Seward - One of the best experts on this subject based on the ideXlab platform.
-
mirvetuximab soravtansine imgn853 a folate receptor alpha frα targeting Antibody drug conjugate adc in platinum resistant epithelial ovarian cancer eoc patients pts activity and safety analyses in phase i pooled expansion cohorts
Journal of Clinical Oncology, 2017Co-Authors: Kathleen N Moore, David M Omalley, Ursula A Matulonis, Jason A Konner, Raymond P Perez, Todd Michael Bauer, Lucy Gilbert, Shelly Seward, Rodrigo RuizsotoAbstract:5547Background: The early clinical evaluation of mirvetuximab soravtansine (IMGN853), an ADC that comprises a FRα-Binding Antibody linked to the tubulin-disrupting maytansinoid DM4, has revealed en...
-
imgn853 mirvetuximab soravtansine a folate receptor alpha frα targeting Antibody drug conjugate adc single agent activity in platinum resistant epithelial ovarian cancer eoc patients pts
Journal of Clinical Oncology, 2016Co-Authors: Kathleen N Moore, David M Omalley, Ursula A Matulonis, Jason A Konner, Raymond P Perez, Todd Michael Bauer, Shelly Seward, Woondong Jeong, Lainie P Martin, Yinghui ZhouAbstract:5567Background: IMGN853 (mirvetuximab soravtansine) is an ADC, comprising a FRα-Binding Antibody linked to the tubulin-disrupting maytansinoid, DM4. Here we report on the IMGN853 monotherapy expans...
-
preliminary single agent activity of imgn853 a folate receptor alpha fr alpha targeting Antibody drug conjugate adc in platinum resistant epithelial ovarian cancer eoc patients pts phase i trial
Journal of Clinical Oncology, 2015Co-Authors: Kathleen N Moore, David M Omalley, Raymond P Perez, Todd Michael Bauer, Shelly Seward, Woondong Jeong, Maurice Kirby, Yinghui Zhou, Mary F MichenzieAbstract:5518 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC that comprises a FRα-Binding Antibody conjugated with the potent maytansinoid, DM4. Methods: This phase I trial evaluates the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of IMGN853 in pts with FRα-positive solid tumors. A recommended phase II dose (RP2D) of 6.0 mg/kg, administered once every three weeks using adjusted ideal body weight was established in the dose-finding phase. Preliminary evidence of antitumor activity is being investigated at the RP2D in disease-specific cohorts of pts with platinum-resistant EOC and relapsed/refractory endometrial carcinoma. Here we report preliminary clinical activity (partial PR or complete CR response, CA125 response, SD ≥ 6 cycles) at the RP2D in pts with platinum-resistant EOC. Results: To date, 14 platinum-resistant EOC pts have been treated at the RP2D: 2 in dose escalation; 12 in the expansion cohort. All pts were heavily pretreated (mean: 4.5; range 2-12 prior tr...
-
phase 1 study of imgn853 a folate receptor alpha fr alpha targeting Antibody drug conjugate adc in patients pts with epithelial ovarian cancer eoc and other fra positive solid tumors
Journal of Clinical Oncology, 2015Co-Authors: Hossein Borghaei, David M Omalley, Raymond P Perez, Todd Michael Bauer, Shelly Seward, Woondong Jeong, Maurice Kirby, Mary F Michenzie, Gurudatt Chandorkar, Rodrigo RuizsotoAbstract:5558 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC comprising a FRα-Binding Antibody and potent maytansinoid, DM4. Methods: This Phase 1 trial is being conducted to determine safety, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, recommended phase 2 dose (RP2D) and evidence of activity of IMGN853 in pts with EOC or other FRa-positive solid tumors. As previously reported, the occurrence of ocular adverse events (AEs) was associated with peak drug exposure and pt weight. Dosing by adjusted ideal body weight (AIBW) instead of total body weight (TBW) was implemented to decrease PK variability. Two dosing schedules are being evaluated; (A) once every 3 weeks and (B) Days 1, 8, and 15, every 4 weeks. Results: Fifty nine pts enrolled to dose escalation to date, 44 (30 TBW; 14 AIBW) pts in A, 16 (AIBW) in B. RP2D for A was determined to be 6.0 mg/kg, while dose finding in B continues. Exposure to IMGN853 increased with an increase in dose in a more than dose-proportional...
-
preliminary single agent activity of imgn853 a folate receptor alpha fr alpha targeting Antibody drug conjugate adc in platinum resistant epithelial ovarian cancer eoc patients pts phase i trial
Journal of Clinical Oncology, 2015Co-Authors: Kathleen N Moore, David M Omalley, Raymond P Perez, Todd Michael Bauer, Shelly Seward, Woondong Jeong, Maurice Kirby, Lainie P Martin, Amit M Oza, Yinghui ZhouAbstract:5518 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC that comprises a FRα-Binding Antibody conjugated with the potent maytansinoid, DM4. Methods: This phase I trial evaluates...